HC Wainwright Reiterates Buy Rating for Sensei Biotherapeutics (NASDAQ:SNSE)

Sensei Biotherapeutics (NASDAQ:SNSE)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $4.00 price target on the stock.

Sensei Biotherapeutics Price Performance

SNSE stock opened at $0.51 on Friday. The firm has a fifty day moving average price of $0.47 and a two-hundred day moving average price of $0.49. Sensei Biotherapeutics has a 1-year low of $0.38 and a 1-year high of $1.94. The firm has a market cap of $12.78 million, a price-to-earnings ratio of -0.43 and a beta of 0.16.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its earnings results on Friday, March 28th. The company reported ($0.27) EPS for the quarter, meeting analysts’ consensus estimates of ($0.27). As a group, analysts expect that Sensei Biotherapeutics will post -1.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. XTX Topco Ltd increased its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 62,903 shares of the company’s stock after purchasing an additional 48,977 shares during the quarter. XTX Topco Ltd owned about 0.25% of Sensei Biotherapeutics worth $31,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.